Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); levodopa, quantity: 100 mg; entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: povidone; iron oxide yellow; croscarmellose sodium; mannitol; glycerol; maize starch; titanium dioxide; magnesium stearate; polysorbate 80; hypromellose; sucrose; iron oxide red - l.c.e. sandoz 100/25/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - medroxyprogesterone acetate 100mg;   - tablet - 100 mg - active: medroxyprogesterone acetate 100mg   excipient: docusate sodium gelatin hydrolysate isopropyl alcohol macrogol 400 magnesium stearate maize starch microcrystalline cellulose purified water sodium benzoate sodium starch glycolate - provera 100mg and 200mg tablets are indicated as adjunctive and/or palliative treatment of recurrent and/or metastatic endometrial or renal carcinoma and, in the treatment of hormonally-dependent, recurrent breast cancer in post-menopausal women.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - spironolactone 100mg - tablet - 100 mg - active: spironolactone 100mg excipient: erythrosine lactose monohydrate magnesium stearate microcrystalline cellulose peppermint oil polysorbate 80 povidone purified talc quinoline yellow sodium starch glycolate starch sunset yellow fcf - essential hypertension; oedematous conditions including congestive heart failure, cirrhosis of the liver, (with or without ascites) and the nephrotic syndrome; idiopathic oedema; diagnosis and treatment of primary aldosteronism, as adjunctive therapy in malignant hypertension; in hypokalaemia when other measures are considered inappropriate or inadequate; prophylaxis of hypokalaemia in patients taking digitalis when other measures are considered inadequate or inappropriate.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - temozolomide 100mg;   - capsule - 100 mg - active: temozolomide 100mg   excipient: colloidal silicon dioxide gelatin lactose sodium starch glycolate stearic acid tartaric acid tekprint black sw-9008 - temaccord capsules are indicated for the treatment of patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - temozolomide, quantity: 100 mg - capsule, hard - excipient ingredients: gelatin; titanium dioxide; purified water; colloidal anhydrous silica; tartaric acid; sodium starch glycollate; stearic acid; iron oxide red; lactose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - temozolomide, quantity: 100 mg - capsule, hard - excipient ingredients: gelatin; titanium dioxide; purified water; colloidal anhydrous silica; tartaric acid; sodium starch glycollate; stearic acid; iron oxide red; lactose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - temozolomide, quantity: 100 mg - capsule, hard - excipient ingredients: tartaric acid; sodium lauryl sulfate; iron oxide red; lactose; colloidal anhydrous silica; stearic acid; gelatin; sodium starch glycollate; titanium dioxide; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; iron oxide black; simethicone; strong ammonia solution; potassium hydroxide - temodal capsules are indicated for the treatment of patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment; recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy. temodal capsules are also indicated as first line treatment for patients with advanced metastatic malignant melanoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - temozolomide, quantity: 100 mg - capsule, hard - excipient ingredients: stearic acid; tartaric acid; colloidal anhydrous silica; purified water; microcrystalline cellulose; gelatin; sodium starch glycollate; iron oxide red; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - temozolomide is indicated for the treatment of:,- patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment. - recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - temozolomide, quantity: 100 mg - capsule, hard - excipient ingredients: gelatin; sodium starch glycollate; stearic acid; purified water; colloidal anhydrous silica; microcrystalline cellulose; tartaric acid; iron oxide black; titanium dioxide; iron oxide red; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol absolute; ethanol; shellac; sulfuric acid - temozolomide is indicated for the treatment of:,- patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment. - recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

australian nuclear science and technology organisation t/a ansto - sodium iodide(123i), quantity: 100 mbq - capsule - excipient ingredients: dibasic sodium phosphate heptahydrate; sodium bicarbonate; sodium thiosulfate pentahydrate; sodium hydroxide; purified water; sunset yellow fcf; quinoline yellow; titanium dioxide; brilliant blue fcf; carmoisine; gelatin; ethanol; shellac; pharmaceutical glaze; carbon black - sodium iodide [123] diagnostic capsules are for diagnostic imaging of thyroid tissue.